Strs Ohio Purchases New Position in Becton, Dickinson and Company $BDX

Key Points

• Strs Ohio acquired a new position by purchasing 233,468 shares of Becton, Dickinson and Company, valued at approximately $53.5 million, representing around 0.08% of the company.
• Insider trading activity included EVP Michael David Garrison selling 1,185 shares for about $213,643, while Director Claire Fraser sold 863 shares valued at roughly $165,955.
• Becton, Dickinson and Company reported better-than-expected earnings, with $3.68 EPS for the quarter, surpassing estimates and reflecting a 10.4% year-over-year revenue increase.

Strs Ohio purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 233,468 shares of the medical instruments supplier's stock, valued at approximately $53,478,000. Strs Ohio owned approximately 0.08% of Becton, Dickinson and Company as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Northcape Wealth Management LLC lifted its position in shares of Becton, Dickinson and Company by 0.5% in the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock worth $2,248,000 after buying an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 5.7% during the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock valued at $225,000 after buying an additional 53 shares during the last quarter. Brady Family Wealth LLC grew its stake in Becton, Dickinson and Company by 1.2% in the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after purchasing an additional 53 shares in the last quarter. Diversified Trust Co lifted its holdings in Becton, Dickinson and Company by 4.7% during the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after buying an additional 53 shares during the period. Finally, REAP Financial Group LLC lifted its holdings in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Claire Fraser sold 863 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $192.30, for a total transaction of $165,954.90. Following the completion of the sale, the director owned 23,143 shares of the company's stock, valued at $4,450,398.90. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Morgan Stanley boosted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their price target for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of "Hold" and a consensus target price of $211.44.

Becton, Dickinson and Company Price Performance

BDX opened at $188.57 on Thursday. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a 50-day moving average of $185.95 and a 200-day moving average of $192.31. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a market capitalization of $54.05 billion, a P/E ratio of 33.91, a PEG ratio of 1.42 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same period in the previous year, the business posted $3.50 EPS. Becton, Dickinson and Company's revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.